Anti-BCMA CAR-T Cell Therapy in Relapsed/Refractory Multiple Myeloma Patients With Extramedullary Disease: A Single Center Analysis of Two Clinical Trials

BACKGROUND: The prognosis of relapsed/refractory multiple myeloma (RRMM) patients with the extramedullary disease was significantly poor. Extramedullary multiple myeloma (EMM) patients gained limited benefits from traditional drugs. Anti-B cell maturation antigen (BCMA) chimeric antigen receptor (CA...

Descripción completa

Detalles Bibliográficos
Autores principales: Que, Yimei, Xu, Menglei, Xu, Yanjie, Almeida, Varlene Daniela Fernandes, Zhu, Li, Wang, Zhiqiong, Wang, Ying, Liu, Xian, Jiang, Lijun, Wang, Di, Li, Chunrui, Zhou, Jianfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589080/
https://www.ncbi.nlm.nih.gov/pubmed/34777368
http://dx.doi.org/10.3389/fimmu.2021.755866

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8589080/
https://www.ncbi.nlm.nih.gov/pubmed/34777368
http://dx.doi.org/10.3389/fimmu.2021.755866

Ejemplares similares